Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib

References

• Casanova M, Meazza C, Favini F, Fiore M, Morosi C, Ferrari A. Rhabdomyosarcoma of the extremities: a focus on tumors arising in the hand and foot. Pediatr Hematol Oncol. 2009;26(5):321–331. doi:10.1080/0888001090296436719579078
   PubMed Web of Science ®Google Scholar
• Gurria JP, Dasgupta R. Rhabdomyosarcoma and extraosseous ewing sarcoma. Children. 2018;5(12):165. doi:10.3390/children5120165
   Google Scholar
• Ognjanovic S, Linabery A, Charbonneau G, Ross J. Trends in childhood RMS incidence and survival in the US. Cancer. 2009;115(18):4218–4226. doi:10.1002/cncr.24465.Trends19536876
   PubMed Web of Science ®Google Scholar
• Hoang NT, Acevedo LA, Mann MJ, Tolani B. A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Manag Res. 2018;10:1089–1114. doi:10.2147/CMAR.S15964129785138
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Obrist F, et al. Trial watch:: oncolytic viruses for cancer therapy. Oncoimmunology. 2014;3:e28694. doi:10.4161/onci.2869425097804
   PubMed Web of Science ®Google Scholar
• Kinn VG, Hilgenberg VA, MacNeill AL. Myxoma virus therapy for human embryonal rhabdomyosarcoma in a nude mouse model. Oncolytic Virother. 2016;5:59–71. doi:10.2147/OV.S10883127579297
   PubMed Web of Science ®Google Scholar
• Gentschev I, Adelfinger M, Josupeit R, et al. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One. 2012;7(5):e37239. doi:10.1371/journal.pone.003723922615950
   PubMed Web of Science ®Google Scholar
• Cinatl J Jr, Cinatl J, Michaelis M, et al. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res. 2003;63(7):1508–1514.12670897
   PubMed Web of Science ®Google Scholar
• MacNeill AL, Moldenhauer T, Doty R, Mann T. Myxoma virus induces apoptosis in cultured feline carcinoma cells. Res Vet Sci. 2012;93(2):1036–1038. doi:10.1016/j.rvsc.2011.10.01622100245
   PubMed Web of Science ®Google Scholar
• Urbasic AS, Hynes S, Somrak A, et al. Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene. Am J Vet Res. 2012;73(8):1252–1261. doi:10.2460/ajvr.73.8.125222849686
   PubMed Web of Science ®Google Scholar
• Wang F, Ma Y, Barrett JW, et al. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol. 2004;5(1):1266–1274. doi:10.1038/ni113215502830
   PubMed Web of Science ®Google Scholar
• Woo Y, Kelly KJ, Stanford MM, et al. Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann Surg Oncol. 2008;15(8):2329–2335. doi:10.1245/s10434-008-9924-z18454298
   PubMed Web of Science ®Google Scholar
• Fenner F, Woodroffe GM. The pathogenesis of infectious myxomatosis: the mechanism of infection and the immunological response in the European rabbit (Oryctolagus cuniculus). Br J Exp Pathol. 1953;34(4):400–411.13093911
   PubMedGoogle Scholar
• Fenner F. Adventures with poxviruses of vertebrates. FEMS Microbiol Rev. 2000;24:123–133. doi:10.1111/j.1574-6976.2000.tb00536.x10717311
   PubMed Web of Science ®Google Scholar
• Gorski J, Mizak B, Chrobocinska M. Control of rabbit myxomatosis in Poland. Rev Sci Tech. 1994;13(3):869–879. doi:10.20506/rst.13.3.8037949359
   PubMed Web of Science ®Google Scholar
• McCabe VJ, Tarpey I, Spibey N. Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein. Vaccine. 2002;20(19):2454–2462. doi:10.1016/S0264-410X(02)00186-X12057600
   PubMed Web of Science ®Google Scholar
• McCabe VJ, Spibey N. Potential for broad-spectrum protection against feline calicivirus using an attenuated myxoma virus expressing a chimeric FCV capsid protein. Vaccine. 2005;23(46–47):5380–5388. doi:10.1016/j.vaccine.2005.05.03816176851
   PubMed Web of Science ®Google Scholar
• Pignolet B, Boullier S, Gelfi J, et al. Safety and immunogenicity of myxoma virus as a new viral vector for small ruminants. J Gen Virol. 2008;89(Pt 6):1371–1379. doi:10.1099/vir.0.83595-018474552
   PubMed Web of Science ®Google Scholar
• Thorne SH, Bartlett DL, Kirn DH. The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? CurrGene Ther. 2005;5:429–443.
   Google Scholar
• Chaudhri G, Panchanathan V, Buller RML, et al. Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc Natl Acad Sci U S A. 2004;101(24):9057–9062. doi:10.1073/pnas.040294910115184649
   PubMed Web of Science ®Google Scholar
• Xu R, Johnson AJ, Liggitt D, Bevan MJ. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol. 2004;172(1):6265–6271. doi:10.4049/jimmunol.172.10.626515128815
   PubMed Web of Science ®Google Scholar
• Tosic V, Thomas DL, Kranz DM, et al. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity. PLoS One. 2014;9(10):e109801. doi:10.1371/journal.pone.010980125329832
   PubMed Web of Science ®Google Scholar
• Doty RA, McFadden G, Roy EJ, MacNeill AL. Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma. Oncolytic Virother. 2013;2:1–17. doi:10.2147/OV.S3797125866742
   PubMedGoogle Scholar
• Lun X, Alain T, Zemp FJ, et al. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res. 2010;70(2):598–608. doi:10.1158/0008-5472.CAN-09-151020068158
   PubMed Web of Science ®Google Scholar
• Stanford MM, Shaban M, Barrett JW, et al. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther. 2008;16(1):52–59. doi:10.1038/sj.mt.630034817998900
   PubMed Web of Science ®Google Scholar
• Thomas DL, Doty R, Tosic V, et al. Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer Immunol Immunother. 2011;60(10):1461–1472. doi:10.1007/s00262-011-1045-z21656158
   PubMed Web of Science ®Google Scholar
• Lun X, Yang W, Alain T, et al. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. 2005;65(2):9982–9990. doi:10.1158/0008-5472.CAN-05-120116267023
   PubMed Web of Science ®Google Scholar
• Bartee E, McFadden G. Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine. 2009;47(3):199–205. doi:10.1016/j.cyto.2009.06.00619640730
   PubMed Web of Science ®Google Scholar
• MacNeill AL, Turner PC, Moyer RW. Mutation of the Myxoma virus SERP2 P1-site to prevent proteinase inhibition causes apoptosis in cultured RK-13 cells and attenuates disease in rabbits, but mutation to alter specificity causes apoptosis without reducing virulence. Virology. 2006;356(1–2):12–22. doi:10.1016/j.virol.2006.07.04916959285
   PubMed Web of Science ®Google Scholar
• Zoetis. APQ1213211 © 2014 Zoetis Inc. All rights reserved. Available from: https://www.zoetisus.com/products/dogs/apoquel/pdf/apoqueltechnicalmonograph.pdf. Accessed 512, 2020.
   Google Scholar
• Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry M. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317–324. doi:10.1111/jvp.1210124495176
   PubMed Web of Science ®Google Scholar
• Taniguchi E, Nichijo K, McCleish A, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 2008;27(51):51. doi:10.1038/onc.2008.255
   Web of Science ®Google Scholar
• Liu J, Wennier S, Reinhard M, Roy E, MacNeill A, McFadden G. Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. J Virol. 2009;83(11):5933–5938. doi:10.1128/JVI.00204-0919279088
   PubMed Web of Science ®Google Scholar
• Nathaniel R, MacNeill AL, Wang YX, Turner PC, Moyer RW. Cowpox virus CrmA, Myxoma virus SERP2 and baculovirus P35 are not functionally interchangeable caspase inhibitors in poxvirus infections. J Gen Virol. 2004;85:1267–1278. doi:10.1099/vir.0.79905-015105544
   PubMed Web of Science ®Google Scholar
• Fukuyama T, Ganchingco JR, Bäumer W. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib. Eur J Pharmacol. 2017;794(November2016):20–26. doi:10.1016/j.ejphar.2016.11.02027847179
   PubMed Web of Science ®Google Scholar
• Fukuyama T, Ehling S, Cook E, Bäumer W, Baumer W. Topically administered janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J Pharmacol Exp Ther. 2015;354(3):394–405. doi:10.1124/jpet.115.22378426159873
   PubMed Web of Science ®Google Scholar
• MacNeill AL, Moldawer LL, Moyer RW. The role of the cowpox virus crmA gene during intratracheal and intradermal infection of C57BL/6 mice. Virology. 2009;384(1):151–160. doi:10.1016/j.virol.2008.10.04119056101
   PubMed Web of Science ®Google Scholar
• O’Shea JJ. Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis. 2004;63(SUPPL. 2):67–71. doi:10.1136/ard.2004.02829014672894
   PubMed Web of Science ®Google Scholar
• Liu G, Friggeri A, Yang Y, Park YJ, Tsuruta Y, Abraham E. miR-147, a microRNA that is induced upon toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc Natl Acad Sci U S A. 2009;106(37):15819–15824. doi:10.1073/pnas.090121610619721002
   PubMed Web of Science ®Google Scholar